Paper experimental footprint (reported)

Notes: numbers derived from methods and results: the authors performed 80 ChIP-seq experiments (multiple factors & replicates), several RNA-seq assays, 5 distinct in vivo enhancer perturbation screens and multiplexed screens (methods; GEO GSE132216) Li et al., experimental footprint

Mechanistic summary (schematic)

Mechanistic claims are supported by ChIP-seq showing H3K27ac increases (activation) and concurrent H3K4me1/2 loss + H3K9me3 gain (repression) at targeted enhancers after enCRISPRa/enCRISPRi targeting; TF (GATA1/TAL1) binding loss was observed with enCRISPRi at HS2 (β-globin LCR) in K562 cells Li et al., ChIP-seq enhancer reprogramming

Critical strengths

• Rational dual-effector design — using p300+VP64 for activation and LSD1+KRAB for repression is mechanistically coherent (writes/erases enhancer marks) and the authors show cooperative activity beyond single-effectors Li et al., dual-effector evidence
• Multiscale demonstration — in vitro (HEK293T/K562/Jurkat), xenograft, and in vivo KI mouse enhancer screens provide functional endpoints (gene expression, proliferation, disease progression, lineage output) rather than only molecular marks Li et al., multiscale functional assays
• Allele-specific targeting — sgRNAs designed to target a 12-bp insertion in the TAL1 SE (mutant allele) demonstrate allele-specific activation with in vivo phenotype, a rigorous functional test of enhancer causality in cancer cells Li et al., TAL1 allele-specific activation

Key limitations & blindspots

• Limited benchmark breadth: quantitative head-to-head comparisons vs alternative state-of-the-art platforms (e.g., SAM, dxCas9-VPR, SunTag, CRISPRi-MeCP2/KRAB-MeCP2 combinations, or dual-SpCas9 deletion screens) are narrow — mainly a few loci (MYOD, IL1RN, OCT4, HS2) rather than genome-wide across variable chromatin contexts. This constrains generality Li et al., benchmarking scope
• Off-target characterization: the authors report dCas9 ChIP-seq with minimal off-target enrichment at the HS2 locus, but genome-wide specificity metrics (e.g., GUIDE-seq, CIRCLE-seq, methylome-wide off-target histone or DNA methylation readouts, or unbiased RNA-seq DE analysis across more contexts) are limited — especially for epigenome writers which can spread effects Li et al., off-target reporting
• Model dependence and cell-type scope: K562 (erythroid), Jurkat (T-ALL), HEK293T and KH2 ESC-derived mouse models are standard but limited — enhancer dependencies are highly context-specific and results may not generalize to primary human tissues or other lineages without further validation Li et al., model scope
• Preprint status: not peer-reviewed as of the deposit; some methods, sample-size details, and raw plots require careful independent verification (though data are deposited at GEO: GSE132216) Li et al., preprint and data

Context & novelty

Enhancer perturbation has been pursued via reporter assays, saturating deletions, and single-effector CRISPRa/i systems (e.g., dCas9-p300, SAM, dCas9-KRAB, dCas9-LSD1). Li et al. combine epigenetic writer + transcriptional effector in the same recruitment topology to more directly rewrite enhancer histone marks and TF occupancy — an advance in modality that enables both loss- and gain-of-function at enhancers in native chromatin and in vivo (not previously shown at the same scale) Li et al., contextual placement

For readers: Hilton et al., 2015 established dCas9-p300 as an epigenome editor for enhancers; Li et al. extend this by combining p300 with VP64 recruitment (MS2–MCP) for more potent activation and similarly combine LSD1+KRAB for repression Hilton et al., dCas9-p300

Reproducibility & available resources

• Raw and processed ATAC/ChIP/RNA-seq data: GEO accession GSE132216 (paper statement) GEO GSE132216 data deposition
• Methods: detailed cloning and mouse KI strategy included; many plasmids reference Addgene backbones and pre-existing constructs (p300-Core, MS2 systems) enabling reuse; exact sgRNA sequences are provided in Supplementary Table S2 (paper) Li et al., methods/data access

Practical takeaways & recommended next experiments

1. Benchmark across chromatin states: run matched enCRISPRa/enCRISPRi, SAM, dCas9-p300, dCas9-KRAB-MeCP2, and dual-cut deletion (dual-SpCas9 pgRNA) across a panel of enhancers stratified by ATAC/H3K27ac/H3K4me1 to quantify effect size ⇒ use DESeq2 + MAGeCK-style depletion metrics for comparability (useful comparator: benchmarking work for CRE perturbation tools) Li et al., benchmarking suggestion
2. Orthogonal off-target mapping: perform unbiased off-target assays (GUIDE-seq/CIRCLE-seq for DNA binding events, CUT&RUN for recruited effector occupancy, and global histone mark profiling) to rule out distal epigenetic spreading; include vehicle and non-targeting sgRNA controls and multiple genomic loci Li et al., off-target needs
3. Time-course epigenetic & transcriptional dynamics: map H3K27ac/H3K4me1/2/H3K9me3 + TF binding + nascent transcription (PRO-cap/PRO-seq/GRO-seq) at early and late timepoints after enCRISPR targeting to distinguish primary chromatin changes from secondary promoter effects and enhancer-promoter feedback Li et al., temporal mechanistic point
4. Assess RNA (eRNA) roles: combine enCRISPR perturbations with eRNA-specific depletion (ASOs or Cas13) at targeted enhancers to test whether transcription per se or chromatin marks mediate observed transcriptional effects; leverage eRNA literature for expected complexities Li et al., eRNA suggestion

Quick metrics (expert-critical)

• Paper novelty: 7/10 — novel combination of dual effectors targeted to enhancers with in vivo multiplexed screening (first demonstration at this scale) Li et al., novelty
• Paper quality: 7/10 — solid experimental design and multiple orthogonal assays; limited by preprint status and incomplete genome-scale benchmarking/off-target orthogonals.
• Generality: 6/10 — methods likely generalizable, but biological dependency on cell context and variability across enhancers means broad claims require further validation.
• Usefulness: 8/10 — provides a practical toolkit and an inducible mouse model enabling in vivo enhancer screens; valuable resource for epigenetic functional studies.
• Reproducibility: 6/10 — data deposited to GEO (GSE132216) and methods described; full reproducibility would be strengthened by sharing plasmids, mouse lines, and deeper off-target datasets.
• Explanatory depth: 7/10 — mechanistic links shown between effector activities and histone mark changes; causal temporal dynamics and eRNA roles need deeper probing.